Slogger,
We acknowledge that the development pipeline seems to be blocked. This leaves Acrux vulnerable when TRT is questioned as being its only weapon. Unless further positive details are forthcoming of R&D dollar use, what about acquisitions? There are numerous listed small biotechs (and probably unlisted) close to realising potential, that I believe would have synergies with being under an Acrux umbrella. I can think of a few examples that would be a nice fit. It seems to me that Acrux may now be big enough not to need to work from the ground up. Does this sound realistic? Might it be wise for the company to start looking? It is certainly one way of providing a succession plan. It would also give a new product better access to partners like Eli Lilly maybe. What do you think>? The other option I thought of is merging with a similar size organisation. I can think of one off hand that might seem good on paper, but it would have to be a pretty special relationship for a merge to work.
It seems to me that maybe it is time for Acrux to at least consider its options.
Lairy
Add to My Watchlist
What is My Watchlist?
